Related Experiment Videos
Soluble intercellular adhesion molecule-1 level in sera is elevated in perennial allergic rhinitis
1Department of Otolaryngology, Osaka City University Medical School, Abeno, Osaka, Japan.
The Laryngoscope
|July 1, 1997
Summary
Serum soluble intercellular adhesion molecule-1 (sICAM-1) is elevated in perennial allergic rhinitis patients. Immunotherapy may decrease sICAM-1 over time, suggesting its potential role in monitoring treatment efficacy.
Area of Science:
- Immunology
- Allergology
- Biochemistry
Background:
- Soluble intercellular adhesion molecule-1 (sICAM-1) is implicated in allergic disorders.
- Serum sICAM-1 levels in perennial allergic rhinitis (PAR) are not well-established.
- Understanding sICAM-1 in PAR is crucial for diagnostic and therapeutic insights.
Purpose of the Study:
- To compare serum sICAM-1 levels in PAR patients versus nonatopic controls.
- To investigate the effect of immunotherapy on serum sICAM-1 levels in PAR.
- To explore the correlation between sICAM-1 and symptom severity during immunotherapy.
Main Methods:
- Serum sICAM-1 was quantified using a sandwich enzyme-linked immunosorbent assay (ELISA).
- The study included 137 patients with PAR and 20 nonallergic volunteers.
- Longitudinal measurements were considered for patients undergoing immunotherapy.
Main Results:
- Untreated PAR patients exhibited significantly higher serum sICAM-1 levels compared to controls.
- Immunotherapy demonstrated a suppressive effect on sICAM-1, noticeable after prolonged treatment.
- A significant correlation was found between sICAM-1 levels and nasal symptom scores in patients on immunotherapy.
Conclusions:
- Serum sICAM-1 is elevated in perennial allergic rhinitis.
- Decreased sICAM-1 may reflect the mechanism of action of immunotherapy in PAR.
- Serum sICAM-1 holds potential as a biomarker for monitoring immunotherapy effectiveness in PAR.